BIOMARKER:

RET mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) selpercatinib Sensitive : A1 ESMO 2022 - 3wk	selpercatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks selpercatinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
RET mutation	Thyroid Gland Anaplastic Carcinoma	RET mutation	Thyroid Gland Anaplastic Carcinoma	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	TPX-0046 Sensitive: C2 – Inclusion Criteria TPX-0046 Sensitive : C2	TPX-0046 Sensitive: C2 – Inclusion Criteria TPX-0046 Sensitive : C2
RET mutation	Non Small Cell Lung Cancer	RET mutation	Non Small Cell Lung Cancer	TPX-0046 Sensitive: C2 – Inclusion Criteria TPX-0046 Sensitive : C2	TPX-0046 Sensitive: C2 – Inclusion Criteria TPX-0046 Sensitive : C2
RET mutation	Non Small Cell Lung Cancer	RET mutation	Non Small Cell Lung Cancer	BOS-172738 Sensitive: C2 – Inclusion Criteria BOS-172738 Sensitive : C2	BOS-172738 Sensitive: C2 – Inclusion Criteria BOS-172738 Sensitive : C2
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	BOS-172738 Sensitive: C2 – Inclusion Criteria BOS-172738 Sensitive : C2	BOS-172738 Sensitive: C2 – Inclusion Criteria BOS-172738 Sensitive : C2
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	RET inhibitor Sensitive: C3 – Early Trials RET inhibitor Sensitive : C3	RET inhibitor Sensitive: C3 – Early Trials RET inhibitor Sensitive : C3
RET mutation	Non Small Cell Lung Cancer	RET mutation	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
RET mutation	Melanoma	RET mutation	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
RET mutation	Thyroid Gland Carcinoma	RET mutation	Thyroid Gland Carcinoma	LDD-2633 Sensitive: D – Preclinical LDD-2633 Sensitive : D	LDD-2633 Sensitive: D – Preclinical LDD-2633 Sensitive : D
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D
RET mutation	Thyroid Gland Carcinoma	RET mutation	Thyroid Gland Carcinoma	CB-228 + AST-487 Sensitive: D – Preclinical CB-228 + AST-487 Sensitive : D	CB-228 + AST-487 Sensitive: D – Preclinical CB-228 + AST-487 Sensitive : D
RET mutation	Thyroid Gland Carcinoma	RET mutation	Thyroid Gland Carcinoma	AST-487 Sensitive: D – Preclinical AST-487 Sensitive : D	AST-487 Sensitive: D – Preclinical AST-487 Sensitive : D